[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,431,493
  • Shares Outstanding, K 206,553
  • Annual Sales, $ 0 K
  • Annual Income, $ -505,610 K
  • EBIT $ -566 M
  • EBITDA $ -566 M
  • 60-Month Beta 0.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.30

Options Overview Details

View History
  • Implied Volatility 74.43% (+3.11%)
  • Historical Volatility 32.91%
  • IV Percentile 59%
  • IV Rank 19.74%
  • IV High 173.11% on 10/22/25
  • IV Low 50.17% on 06/18/26
  • Expected Move (DTE 17) 1.74 (4.27%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 378
  • Volume Avg (30-Day) 289
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 26,833
  • Open Int (30-Day) 26,357
  • Expected Range 39.08 to 42.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 6
  • High Estimate $-0.63
  • Low Estimate $-0.79
  • Prior Year $-0.73
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.78 +10.98%
on 08/03/26
45.42 -10.13%
on 08/19/26
+2.20 (+5.70%)
since 07/31/26
3-Month
30.24 +34.99%
on 06/09/26
45.42 -10.13%
on 08/19/26
+7.52 (+22.58%)
since 05/29/26
52-Week
14.47 +182.10%
on 08/29/25
45.42 -10.13%
on 08/19/26
+26.00 (+175.44%)
since 08/28/25

Most Recent Stories

More News
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK , Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) ...

IMVT : 40.82 (-0.92%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat...

IMVT : 40.82 (-0.92%)
ROIV : 34.64 (-0.20%)
Immunovant's Pipeline Momentum Meets the Reality of a Balance Sheet with Limits

Barchart Research What to Expect from IMVT Earnings IMVT Generated August 5, 2026 Current Price $39.28 EPS Estimate $$-0.66 Consensus Rating Moderate Buy Average Move 9.56% Immunovant's Pipeline Momentum...

IMVT : 40.82 (-0.92%)
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:  IMVT ) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August...

IMVT : 40.82 (-0.92%)
ROIV : 34.64 (-0.20%)
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August...

IMVT : 40.82 (-0.92%)
Immunovant Q4 Earnings Call Highlights

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet...

IMVT : 40.82 (-0.92%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant...

IMVT : 40.82 (-0.92%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in...

IMVT : 40.82 (-0.92%)
Immunovant's Clinical Timeline and Cash Runway Converge at Tomorrow's Report

Barchart Research What to Expect from IMVT Earnings IMVT Generated May 19, 2026 Current Price $26.29 EPS Estimate $$-0.60 Consensus Rating Moderate Buy Average Move 5.66% Immunovant's Clinical Timeline...

IMVT : 40.82 (-0.92%)
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq:  IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026,...

IMVT : 40.82 (-0.92%)
ROIV : 34.64 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 42.80
2nd Resistance Point 42.04
1st Resistance Point 41.43
Last Price 40.82
1st Support Level 40.06
2nd Support Level 39.30
3rd Support Level 38.69

See More

52-Week High 45.42
Last Price 40.82
Fibonacci 61.8% 33.60
Fibonacci 50% 29.94
Fibonacci 38.2% 26.29
52-Week Low 14.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.